Pfizer has increased its full-year adjusted profit guidance due to cost cuts and strong business performance this year. The company’s second-quarter results topped Wall Street’s estimates, driven by revenue from Covid products and some other drugs.
The pharmaceutical giant reported a 10% increase in revenue for the second quarter, primarily due to higher sales of vaccines and antiviral treatments for Covid-19. Pfizer’s Covid vaccine, Comirnaty, generated $381 million in revenue, up 96% from the previous year, while its Covid pill Paxlovid posted $427 million in sales.
The company has also maintained its 2025 revenue forecast of $61 billion to $64 billion. However, it expects a one-time charge of $1.35 billion due to a licensing deal with Chinese drugmaker 3SBio.
Pfizer’s full-year outlook includes tariffs on pharmaceuticals imported into the US and potential changes in US drug prices. The company has received a letter from President Trump calling for lower drug prices, but Pfizer CEO Albert Bourla declined to provide details on the impact of the policy.
The company’s CFO, David Denton, stated that the raised full-year 2025 Adjusted diluted EPS guidance demonstrates confidence in executing strategic priorities and delivering strong results for shareholders. However, the company expects costs related to Trump’s existing tariffs to be less than $100 million.
Pfizer’s shares rose more than 4% on Tuesday following the announcement of the increased profit guidance. The company’s cost-cutting efforts aim to help it recover from the decline of its Covid business and stock price over the past few years.
Source: https://www.cnbc.com/2025/08/05/pfizer-pfe-q2-2025-earnings-report.html